Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience

The repeated waves of the COVID-19 pandemic have highlighted the necessity to optimize vaccine responses in immunocompromised populations. We investigated the safety and immunogenicity of a third, booster, dose of the Pfizer BNT162b2 vaccine in heart transplant (HT) patients.

Source: The Journal of Heart and Lung Transplantation - August 27, 2021 Category: Transplant Surgery Authors: Yael Peled, Eilon Ram, Jacob Lavee, Amit Segev, Shlomi Matezki, Anat Wieder-Finesod, Rebecca Halperin, Michal Mandelboim, Victoria Indenbaum, Itzchak Levy, Leonid Sternik, Ehud Raanani, Arnon Afek, Yitshak Kreiss, Yaniv Lustig, Galia Rahav Tags: Original Clinical Science Source Type: research